Big pharmas have maintained a torrid pace for accessing biotech innovation to help strengthen their product pipelines. As a result it was a great quarter for biotech deal making, according to data compiled by BioWorld Snapshots, seeing 81 transactions completed between biotech companies and pharma firms – approximately 19 percent more than the number of deals completed in the second quarter of this year.